Year-over-year earnings per share growth for the last twelve months: biofrontera-us.com (BFRI)

The quarterly EPS growth rate helps identify the real value of Biofrontera Inc. (BFRI), while 92.40 characterizes this valuation parameter. Specialized temperature-controlled transportation ensures the security of pharmacy supplies. Biofrontera Inc. (BFRI) is scaling the Ameluz system through clinic partnerships while simultaneously introducing new licensed drugs to overcome dependence on a single core product.

This indicator measures the quarterly rate of change in earnings per share, allowing for an assessment of cost management efficiency and the actual profitability of the business. By analyzing the quarterly EPS growth rate, an investor can see how scaling sales of photodynamic therapy drugs activates operating leverage, reducing the burden of fixed marketing costs and increasing the bottom line for Biofrontera Inc. (BFRI).